Pithecellobium clypearia: Amelioration Effect on Imiquimod-Induced Psoriasis in Mice Based on a Tissue Metabonomic Analysis

Pithecellobium clypearia Benth. (accepted name: Archidendron clypearia (Jack) I.C.Nielsen; Mimosaceae), a popular traditional Chinese medicine, has a significant anti-inflammatory effect. The crude water extract of the aerial part of P. clypearia has been clinically applied to treat upper respiratory tract infections, acute gastroenteritis, laryngitis, and pharyngitis. However, the therapeutic mechanism of ethanol fraction of water extract (ESW) of P. clypearia to treat psoriasis should be complemented. The aim of our research was to clarify the protective effects of ESW from P. clypearia against psoriasis-like skin inflammation induced by imiquimod (IMQ) in mice with efficacy indexes and target tissue (spleen and serum) metabolomics. The ingredient of ESW was analyzed by ultrahigh-performance liquid chromatography combined with tandem mass spectrometry (UHPLC-MS/MS) method. The imiquimod-induced psoriatic mouse model was employed to investigate the effect of ESW against psoriasis, where the treatment method was implemented for 6 days both topically (Gel at 5%) and orally (at 2.4 g/kg p.o.). Traditional pharmacodynamic indicators (phenotypic characteristics, psoriasis area and severity index (PASI) score, H&E staining, immunohistochemical staining, the thickness of epidermis, body weight change, and spleen index) were conducted to appraise the efficacy of ESW. Furthermore, a gas chromatography-mass spectrometer (GC-MS) coupled with multivariate analysis was integrated and applied to obtain serum and spleen metabolic profiles for clarifying metabolic regulatory mechanisms of ESW. The current study illustrated that ESW is composed mainly of gallic acid, ethyl gallate, quercitin, 7-O-galloyltricetiflavan, quercetin, and myricetin by UHPLC-MS/MS analysis. ESW could distinctly improve IMQ-induced psoriasis in mouse through reducing PASI score, alleviating tissue damage, restoring spleen index, and inhibiting proliferating cell nuclear antigen (PCNA) expression in psoriasis-like skin tissue. From the metabolomics study, 23 markers with significant changes are involved in eight main pathways in spleen and serum samples, including linoleic acid metabolism and glycine, serine, and threonine metabolism. The current study showed that ESW had obvious antipsoriasis effects on IMQ-induced psoriasis in mice, which might be attributed to regulating the dysfunction of differential biomarkers and related pathways. In summary, ESW of P. clypearia showed a favourable therapeutic effect on IMQ-induced psoriasis, and metabolomics provided insights into the mechanisms of ESW to the treatment of psoriasis.

Download Full-text

Water Extract Influence of Stachytarpheta jamaicensis (L.) Vahl Leaves to Prevent Psoriasis Severity in Animal Model

Indonesian Journal of Pharmaceutical Science and Technology ◽

10.24198/ijpst.v1i1.36335 ◽

2022 ◽

Vol 1 ◽

pp. 39

Author(s):

Encep Abdurahman ◽

Nengdiana Permana ◽

Grace S. Mardiana ◽

Afifah B. Sutjiatmo ◽

Anna Choirunnisa ◽

...

Keyword(s):

Lupus Erythematosus ◽

Dose Range ◽

Water Extract ◽

Severity Index ◽

Current Treatment ◽

Control Group ◽

Effective Activity ◽

Model Animal ◽

Pasi Score ◽

Histological Results

Psoriasis is an autoimmune disease that is characterized by the appearance of lesions on the skin. The current treatment aims to control the symptoms. The efficacy of Stachytarpheta jamaicensis (L.) Vahl’s for autoimmune rheumatoid arthritis and systemic lupus erythematosus has been tested in animal models. The aim of this research was to evaluate the effect of the water extract of S. jamaicensis leaves on psoriasis model animal (male Balb/c mice) induced topically by imiquimod. The water extract of S. jamaicensis leaves is made by boiling. The animal was divided into groups: normal, control, methotrexate 0.2 mg/kgBW, the extract (doses 25, 50 and 100 mg/kgBW). The measured parameters were the Psoriasis Area and Severity Index (PASI) score and skin histopathology. The results showed that all doses of the extract could reduce the PASI score when compared to the control group. Histological results showed that there was a decrease in keratin growth in test animals that were given the extract. Extracts at doses of 25 and 50 mg/kgBW can reduce the thickening of keratin in the epidermis of the back and ears. It can be concluded that the water extract of S. jamaicensis leaf has the most effective activity to prevent psoriasis recurrence in the dose range of 25 and 50 mg/kgBW.Keywords: Psoriasis, Stachytarpheta jamaicensis leaf water extract, PASI, keratin, imiquimod

Download Full-text

IL-17A, IL-22, IL-6, and IL-21 Serum Levels in Plaque-Type Psoriasis in Brazilian Patients

Mediators of Inflammation ◽

10.1155/2015/819149 ◽

2015 ◽

Vol 2015 ◽

pp. 1-5 ◽

Cited By ~ 23

Author(s):

Priscilla Stela Santana de Oliveira ◽

Pablo Ramon Gualberto Cardoso ◽

Emerson Vasconcelos de Andrade Lima ◽

Michelly Cristiny Pereira ◽

Angela Luzia Branco Pinto Duarte ◽

...

Keyword(s):

Healthy Volunteers ◽

Severity Index ◽

Serum Levels ◽

Statistical Correlation ◽

Control Group ◽

Inflammatory Skin Disease ◽

Serum Samples ◽

Cytokine Detection ◽

Plaque Type ◽

Pasi Score

Psoriasis is a chronic inflammatory skin disease characterized by alterations in cytokines produced by both Th1 and Th17 pathways. The aim of this study was to evaluate serum levels of pivotal cytokines and correlate them with clinical parameters. Serum samples from 53 psoriasis patients and 35 healthy volunteers, matched by the proportion of sex and age ratios, were collected for ELISA cytokine detection. Psoriasis Area and Severity Index (PASI) was assessed at the time of sampling in psoriasis patients. Our findings demonstrate that IL-17A, IL-22, and IL-6 serum concentrations were significantly higher in psoriasis patients than in the control group. No statistical correlation could be found between cytokines concentrations, PASI score, and age in this study. Although our results do not show any correlation between serum levels of IL-17A, IL-22, and IL-6 and disease activity, the present study confirms that they were increased in Brazilian psoriasis patients in comparison to healthy volunteers.

Download Full-text

Nagelpsoriasis: Anti-IL17-Therapie ist erfolgversprechend

Karger Kompass Dermatologie ◽

10.1159/000509299 ◽

2020 ◽

Vol 8 (3) ◽

pp. 111-113

Author(s):

Sandra Philipp

Keyword(s):

Quality Of Life ◽

Severity Index ◽

Primary Objective ◽

Controlled Study ◽

Upper Respiratory Tract ◽

Double Blind ◽

Nail Psoriasis ◽

Patient Questionnaires ◽

Tract Infections

Background: Nail psoriasis is associated with functional impairment, pain and reduced quality of life. Objectives: To demonstrate the superiority of secukinumab over placebo in clearing nail psoriasis as assessed by the Nail Psoriasis Severity Index (NAPSI) at week 16 and over time up to week 132. Presented here is the week 32 interim analysis. Impact on quality of life was assessed by Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA) patient questionnaires. Methods: TRANSFIGURE is a double-blind, randomized, placebo-controlled study in patients with moderate-to-severe plaque and nail psoriasis. Results: The primary objective of this study was met: both doses of secukinumab were superior to placebo at week 16 (NAPSI improvements of -45,3%, -37,9% and -10,8% for secukinumab 300 mg and 150 mg and placebo, respectively, P<0,001). Significant improvements were seen in patients’ quality of life: the NAPPA-Quality of Life total score median decreases at week 16 were 60,9%, 49,9% and 15,8% for secukinumab 300 mg and 150 mg and placebo, respectively (P < 0_001). Improvement in nail psoriasis continued to week 32: NAPSI percentage change reached -63,2% and -52,6% for secukinumab 300 mg and 150 mg, respectively. Skin clearance measured by ≥90% improvement in Psoriasis. Area and Severity Index was significant (rates of 72,5%, 54,0% and 1,7% for secukinumab 300mg and 150mg and placebo at week 16, respectively, P<0,001) and was sustained to week 32. The most common adverse events were nasopharyngitis, headache and upper respiratory tract infections. Conclusion: Secukinumab demonstrated significant and clinically meaningful efficacy and quality-of-life improvements for patients with nail psoriasis up to week 32.

Download Full-text

Ixekizumab: A Review of Its Use for the Management of Moderate to Severe Plaque Psoriasis

Annals of Pharmacotherapy ◽

10.1177/1060028018799982 ◽

2018 ◽

Vol 53 (3) ◽

pp. 276-284 ◽

Cited By ~ 5

Author(s):

Sydney K. Shelton ◽

Sandra R. Bai ◽

Joseph K. Jordan ◽

Amy Heck Sheehan

Keyword(s):

Plaque Psoriasis ◽

Data Extraction ◽

Severity Index ◽

Biological Agents ◽

Phase Iii ◽

Interleukin 17 ◽

Upper Respiratory Tract ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Tract Infections

Objective: To review the efficacy, safety, and place in therapy of ixekizumab for the treatment of moderate to severe plaque psoriasis. Data Sources: PubMed (1966 to July 2018) and clinicaltrials.gov were searched using the terms ixekizumab, LY2439821, interleukin-17, and psoriasis. Study Selection and Data Extraction: Human studies published in peer-reviewed medical journals in English were used. Data Synthesis: The efficacy and safety of ixekizumab has been primarily reported by 4 phase III trials (UNCOVER-1, UNCOVER-2, UNCOVER-3, and UNCOVER-J) and multiple post hoc analyses. The average proportions of patients achieving a 75%, 90%, and 100% reduction in their Psoriasis Area and Severity Index (PASI) were 89%, 70%, and 38%, respectively, after 12 weeks of therapy. PASI75 was maintained for up to 3 years in 80.5% of participants. Ixekizumab was statistically significantly more effective than ustekinumab, with 76.5%, compared with 59%, of patients achieving PASI90 in 52 weeks. The most common adverse events include nasopharyngitis (14.1%), upper respiratory tract infections (7.9%), and injection-site reactions (6.8%), which are similar to that for other biological agents. The risk of inflammatory bowel disease may be increased with ixekizumab. Relevance to Patient Care and Clinical Practice: This review summarizes and evaluates clinical data regarding the efficacy and safety of ixekizumab and discusses relevant differences compared with other biological agents used for the management of chronic plaque psoriasis. Conclusions: Ixekizumab is a highly efficacious and well-tolerated treatment option for patients with moderate to severe plaque psoriasis.

Download Full-text